Renaissance Capital logo

AN2 Therapeutics Priced, Nasdaq: ANTX

Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease.

Industry: Health Care

Latest Trade: $2.11 0.00 (0.0%)

First Day Return: +2.7%

Return from IPO: -85.9%

Industry: Health Care

We are a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Epetraborole has broad spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Its novel mechanism of action is enabled by boron chemistry, our core technology approach. We plan to conduct a Phase 2/3 pivotal clinical trial in treatment-refractory Mycobacterium avium complex, or MAC, lung disease, which is the most common type of NTM lung disease. Interim data from our completed Phase 1b dose-ranging study of epetraborole administered orally for 28 days in healthy volunteers in Australia and data from our two nonclinical chronic toxicology studies (six-month rats and nine-month non-human primates) have informed our selection of a 500 mg once-daily dose for our Phase 2/3 pivotal clinical trial in treatment-refractory MAC lung disease patients. We believe our Phase 2/3 pivotal clinical trial design, which is under review by the U.S. Food and Drug Administration, or FDA, has the potential to be sufficient for regulatory approval in the United States
more less
IPO Data
IPO File Date 03/04/2022
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.6
Deal Size ($mm) $69
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/24/2022
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.6
Deal Size ($mm) $69
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
TD Cowen
Leerink Partners
more
Company Data
Headquarters Menlo Park, CA, United States
Founded 2017
Employees 22
Website www.an2therapeutics.com

AN2 Therapeutics (ANTX) Performance